| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TOIThe Oncology Institute, Inc. | 330.56M | 3.36 | -4.73 | 21.33% | -14.38% | -213.36% | 34.31 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 155.41M | 187.51M | 203M | 252.48M | 324.24M | 393.41M |
| Revenue Growth % | - | 0.21% | 0.08% | 0.24% | 0.28% | 0.21% |
| Cost of Goods Sold | 125.46M | 150.64M | 162.16M | 200.39M | 264.67M | 339.42M |
| COGS % of Revenue | 0.81% | 0.8% | 0.8% | 0.79% | 0.82% | 0.86% |
| Gross Profit | 29.94M | 36.88M | 40.85M | 52.09M | 59.57M | 54M |
| Gross Margin % | 0.19% | 0.2% | 0.2% | 0.21% | 0.18% | 0.14% |
| Gross Profit Growth % | - | 0.23% | 0.11% | 0.28% | 0.14% | -0.09% |
| Operating Expenses | 32.59M | 45.07M | 86.71M | 134.04M | 136.59M | 114.11M |
| OpEx % of Revenue | 0.21% | 0.24% | 0.43% | 0.53% | 0.42% | 0.29% |
| Selling, General & Admin | 29.64M | 41.9M | 0 | 0 | 0 | 0 |
| SG&A % of Revenue | 0.19% | 0.22% | - | - | - | - |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 2.94M | 3.18M | 86.71M | 134.04M | 136.59M | 114.11M |
| Operating Income | -2.64M | -8.2M | -45.86M | -81.95M | -77.02M | -60.12M |
| Operating Margin % | -0.02% | -0.04% | -0.23% | -0.32% | -0.24% | -0.15% |
| Operating Income Growth % | - | -2.1% | -4.6% | -0.79% | 0.06% | 0.22% |
| EBITDA | 297.11K | -5.02M | -42.52M | -77.54M | -71.14M | -53.83M |
| EBITDA Margin % | 0% | -0.03% | -0.21% | -0.31% | -0.22% | -0.14% |
| EBITDA Growth % | - | -17.89% | -7.47% | -0.82% | 0.08% | 0.24% |
| D&A (Non-Cash Add-back) | 2.94M | 3.18M | 3.34M | 4.41M | 5.87M | 6.29M |
| EBIT | -2.63M | -14.47M | -45.38M | -72.01M | -60.15M | -60.12M |
| Net Interest Income | -3.38K | -347K | -320K | -4.08M | -6.78M | -7.5M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.38K | 347K | 320K | 4.08M | 6.78M | 7.5M |
| Other Income/Expense | 6.63K | -6.62M | 34.26M | 81.86M | -6.09M | -4.54M |
| Pretax Income | -2.64M | -14.81M | -11.6M | -91K | -83.1M | -64.66M |
| Pretax Margin % | -0.02% | -0.08% | -0.06% | -0% | -0.26% | -0.16% |
| Income Tax | 1.38M | -492.82K | -671K | -243K | -36K | 0 |
| Effective Tax Rate % | 1.52% | 0.97% | 0.94% | -1.67% | 1% | 1% |
| Net Income | -4.02M | -14.32M | -10.93M | 152K | -83.07M | -64.66M |
| Net Margin % | -0.03% | -0.08% | -0.05% | 0% | -0.26% | -0.16% |
| Net Income Growth % | - | -2.56% | 0.24% | 1.01% | -547.5% | 0.22% |
| Net Income (Continuing) | -4.02M | -14.32M | -10.93M | 152K | -83.07M | -64.66M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.06 | -0.24 | -0.16 | -0.21 | -0.92 | -0.71 |
| EPS Growth % | - | -2.85% | 0.33% | -0.31% | -3.38% | 0.23% |
| EPS (Basic) | -0.06 | -0.24 | -0.16 | 0.00 | -0.92 | -0.71 |
| Diluted Shares Outstanding | 64.45M | 59.12M | 66.23M | 80.61M | 73.75M | 75.04M |
| Basic Shares Outstanding | 64.45M | 59.12M | 66.23M | 72.79M | 73.75M | 75.04M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 21.79M | 29.72M | 154.06M | 130.42M | 143.49M | 112.42M |
| Cash & Short-Term Investments | 2.45M | 6M | 114.3M | 73.81M | 82.86M | 49.67M |
| Cash Only | 2.45M | 6M | 114.3M | 14.01M | 33.49M | 49.67M |
| Short-Term Investments | 0 | 0 | 0 | 59.8M | 49.37M | 0 |
| Accounts Receivable | 14.73M | 17.26M | 21.24M | 40.43M | 42.91M | 48.68M |
| Days Sales Outstanding | 34.61 | 33.59 | 38.2 | 58.45 | 48.31 | 45.17 |
| Inventory | 3.89M | 4.35M | 6.44M | 9.26M | 13.68M | 10.04M |
| Days Inventory Outstanding | 11.31 | 10.55 | 14.49 | 16.87 | 18.86 | 10.8 |
| Other Current Assets | 0 | 0 | 875K | 0 | 0 | 4.03M |
| Total Non-Current Assets | 37.73M | 35.97M | 49.38M | 131.25M | 65.75M | 60.3M |
| Property, Plant & Equipment | 1.55M | 2.1M | 4.19M | 33.04M | 40.05M | 37.67M |
| Fixed Asset Turnover | 100.20x | 89.12x | 48.43x | 7.64x | 8.10x | 10.44x |
| Goodwill | 14.08M | 14.23M | 26.63M | 21.42M | 7.23M | 7.23M |
| Intangible Assets | 22M | 19.52M | 18.25M | 17.96M | 17.9M | 14.81M |
| Long-Term Investments | 0 | 0 | -371K | 58.35M | 0 | 0 |
| Other Non-Current Assets | 97.85K | 122K | 320K | 477K | 561K | 589K |
| Total Assets | 59.52M | 65.69M | 203.44M | 261.67M | 209.24M | 172.72M |
| Asset Turnover | 2.61x | 2.85x | 1.00x | 0.96x | 1.55x | 2.28x |
| Asset Growth % | - | 0.1% | 2.1% | 0.29% | -0.2% | -0.17% |
| Total Current Liabilities | 13.59M | 28.61M | 29.8M | 29.72M | 34.79M | 52.22M |
| Accounts Payable | 8.89M | 12.64M | 15.56M | 9.37M | 14.43M | 24.32M |
| Days Payables Outstanding | 25.85 | 30.63 | 35.02 | 17.07 | 19.9 | 26.16 |
| Short-Term Debt | 0 | 5.37M | 183K | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 1000K | 592K | 1000K | 545K | 1000K |
| Other Current Liabilities | 0 | -3.38M | 10.14M | 9.35M | 11.32M | 10.35M |
| Current Ratio | 1.60x | 1.04x | 5.17x | 4.39x | 4.12x | 2.15x |
| Quick Ratio | 1.32x | 0.89x | 4.95x | 4.08x | 3.73x | 1.96x |
| Cash Conversion Cycle | 20.07 | 13.51 | 17.67 | 58.25 | 47.27 | 29.8 |
| Total Non-Current Liabilities | 3.71M | 8.98M | 69.48M | 108.77M | 117.43M | 116.91M |
| Long-Term Debt | 0 | 6.56M | 0 | 80.62M | 86.83M | 93.13M |
| Capital Lease Obligations | 0 | 0 | 0 | 22.06M | 26.49M | 23.22M |
| Deferred Tax Liabilities | 2.96M | 1.61M | 371K | 108K | 32K | 32K |
| Other Non-Current Liabilities | 756.42K | 807K | 69.11M | 5.98M | 4.08M | 527K |
| Total Liabilities | 17.3M | 37.59M | 99.28M | 138.49M | 152.22M | 169.13M |
| Total Debt | 0 | 11.93M | 183K | 108.18M | 119.67M | 123.15M |
| Net Debt | -2.45M | 5.93M | -114.12M | 94.17M | 86.19M | 73.48M |
| Debt / Equity | - | 0.42x | 0.00x | 0.88x | 2.10x | 34.31x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | -8.23x | - | - | - | - | - |
| Interest Coverage | -783.63x | -23.62x | -143.31x | -20.08x | -11.36x | -8.02x |
| Total Equity | 42.22M | 28.1M | 104.16M | 123.17M | 57.02M | 3.59M |
| Equity Growth % | - | -0.33% | 2.71% | 0.18% | -0.54% | -0.94% |
| Book Value per Share | 0.66 | 0.48 | 1.57 | 1.53 | 0.77 | 0.05 |
| Total Shareholders' Equity | 42.22M | 28.1M | 104.16M | 123.17M | 57.02M | 3.59M |
| Common Stock | 0 | 6K | 7K | 7K | 8K | 8K |
| Retained Earnings | -6.02M | -52.31M | -63.23M | -63.08M | -146.15M | -210.81M |
| Treasury Stock | 0 | 0 | 0 | 0 | -1.02M | -1.02M |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | 3.62M | 508K | -32.68M | -61.76M | -36.31M | -26.54M |
| Operating CF Margin % | 0.02% | 0% | -0.16% | -0.24% | -0.11% | -0.07% |
| Operating CF Growth % | - | -0.86% | -65.33% | -0.89% | 0.41% | 0.27% |
| Net Income | -4.02M | -14.32M | -10.93M | 152K | -83.07M | -53.01M |
| Depreciation & Amortization | 2.94M | 3.18M | 3.34M | 4.41M | 5.87M | 6.29M |
| Stock-Based Compensation | 94.01K | 151K | 24.54M | 27.68M | 17.81M | 0 |
| Deferred Taxes | 824.76K | -1.34M | -1.24M | -263K | -76K | 0 |
| Other Non-Cash Items | 326.93K | 11.85M | -33.9M | -73.2M | 20.79M | 2.12M |
| Working Capital Changes | 3.45M | 992K | -14.49M | -20.54M | 2.36M | 18.06M |
| Change in Receivables | -4.44M | -6.76M | -2.99M | -19.66M | -4.5M | -5.77M |
| Change in Inventory | -1.13M | -465K | -1.84M | -1.73M | -4.38M | 3.64M |
| Change in Payables | 5.53M | 3.76M | 2.92M | -6.19M | 5.06M | 9.21M |
| Cash from Investing | -1.2M | -8.84M | -12.15M | -131.61M | 62.64M | 46.21M |
| Capital Expenditures | -1.2M | -1.19M | -2.85M | -5.53M | -4.57M | -3.79M |
| CapEx % of Revenue | 0.01% | 0.01% | 0.01% | 0.02% | 0.01% | 0.01% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | -7.5M | -200K | 0 | 0 | 0 |
| Cash from Financing | -1.81K | 11.89M | 154.01M | 92.21M | -6.85M | -3.49M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 0 | -293K | 141.26M | -8.74M | -5.73M | -3.53M |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | 2.41M | -686K | -35.73M | -67.28M | -40.88M | -30.33M |
| FCF Margin % | 0.02% | -0% | -0.18% | -0.27% | -0.13% | -0.08% |
| FCF Growth % | - | -1.28% | -51.08% | -0.88% | 0.39% | 0.26% |
| FCF per Share | 0.04 | -0.01 | -0.54 | -0.83 | -0.55 | -0.40 |
| FCF Conversion (FCF/Net Income) | -0.90x | -0.04x | 2.99x | -406.29x | 0.44x | 0.41x |
| Interest Paid | 3.38K | 227K | 275K | 224K | 4.51M | 0 |
| Taxes Paid | 61.27K | 207K | 1.73M | 150K | 403K | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -9.52% | -40.73% | -16.52% | 0.13% | -92.2% | -213.36% |
| Return on Invested Capital (ROIC) | -4.99% | -16.66% | -285.72% | -59.27% | -32.04% | -40.94% |
| Gross Margin | 19.27% | 19.67% | 20.12% | 20.63% | 18.37% | 13.73% |
| Net Margin | -2.59% | -7.64% | -5.38% | 0.06% | -25.62% | -16.44% |
| Debt / Equity | - | 0.42x | 0.00x | 0.88x | 2.10x | 34.31x |
| Interest Coverage | -783.63x | -23.62x | -143.31x | -20.08x | -11.36x | -8.02x |
| FCF Conversion | -0.90x | -0.04x | 2.99x | -406.29x | 0.44x | 0.41x |
| Revenue Growth | - | 20.66% | 8.26% | 24.37% | 28.42% | 21.33% |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Health Care, Patient Service | 124.07M | 166.78M | 213.5M | 204.88M |
| Health Care, Patient Service Growth | - | 34.42% | 28.01% | -4.04% |
| Dispensary Revenue | 72.55M | 79.34M | 103.83M | 179.92M |
| Dispensary Revenue Growth | - | 9.36% | 30.87% | 73.27% |
| Fee For Service | 69.79M | 105.44M | 143.13M | 136.2M |
| Fee For Service Growth | - | 51.09% | 35.74% | -4.85% |
| Capitated Revenue | 54.28M | 61.34M | 70.37M | 68.69M |
| Capitated Revenue Growth | - | 13.00% | 14.72% | -2.39% |
| Clinical Research Trials And Other Revenue | 6.38M | 6.36M | 6.9M | 8.61M |
| Clinical Research Trials And Other Revenue Growth | - | -0.38% | 8.58% | 24.83% |
The Oncology Institute, Inc. (TOI) reported $461.0M in revenue for fiscal year 2024. This represents a 197% increase from $155.4M in 2019.
The Oncology Institute, Inc. (TOI) grew revenue by 21.3% over the past year. This is strong growth.
The Oncology Institute, Inc. (TOI) reported a net loss of $66.3M for fiscal year 2024.
The Oncology Institute, Inc. (TOI) has a return on equity (ROE) of -213.4%. Negative ROE indicates the company is unprofitable.
The Oncology Institute, Inc. (TOI) had negative free cash flow of $27.5M in fiscal year 2024, likely due to heavy capital investments.